scholarly journals PND13 ESTIMATING STATE TRANSITIONS IN ALZHEIMER'S DISEASE BY AGE AND GENDER: ANALYSIS FROM A LONGITUDINAL COHORT

2019 ◽  
Vol 22 ◽  
pp. S272
Author(s):  
I. Yunusa ◽  
A. Rane ◽  
I. Sultan ◽  
T. Eguale
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
State Transitions ◽  
Gender Analysis ◽  
Age And Gender ◽  
Longitudinal Cohort ◽  
And Gender

scholarly journals Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer’s Disease

2019 ◽  
Vol 16 (6) ◽  
pp. 495-504
Author(s):  
Chung-Hsien Lin ◽  
Jean Ching-Yuan Fann ◽  
Sam Li-Sheng Chen ◽  
Hsiu-Hsi Chen ◽  
Kuen-Cheh Yang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cost Effectiveness ◽  
Age Groups ◽  
Cost Effectiveness Analysis ◽  
Age And Gender ◽  
Effectiveness Analysis ◽  
Population Average ◽  
Life Years ◽  
And Gender

Background:Immunotherapy for Alzheimer’s disease(AD) has gained momentum in recent years. One of the concerns over its application pertains to Cost-Effectiveness Analysis (CEA) from population average and specific subgroup differences, as such a therapy is imperative for health decisionmakers to allocate limited resources. However, this sort of CEA model considering heterogeneous population with risk factors adjustment has been rarely addressed.Methods:We aimed to show the heterogeneity of CEA in immunotherapy for AD in comparison with the comparator without intervention. Economic evaluation was performed via incremental Cost- Effectiveness Ratio (ICER) and Cost-Effectiveness Acceptability Curve (CEAC) in terms of the Quality- Adjusted Life Years (QALY). First, population-average CEA was performed with and without adjustment for age and gender. Secondly, sub-group CEA was performed with the stratification of gender and age based on Markov process.Results:Given the threshold of $20,000 of willingness to pay, the results of ICER without and with adjustment for age and gender revealed similar results ($14,691/QALY and $17,604/QALY). The subgroup ICER results by different age groups and gender showed substantial differences. The CEAC showed that the probability of being cost-effective was only 48.8%-53.3% in terms of QALY at population level but varied from 83.5% in women aged 50-64 years, following women aged 65-74 years and decreased to 0.2% in men≥ 75 years.Conclusion:There were considerable heterogeneities observed in the CEA of vaccination for AD. As with the development of personalized medicine, the CEA results assessed by health decision-maker should not only be considered by population-average level but also specific sub-group levels.

Age and gender differences for the behavioral phenotypes of 3xTg alzheimer's disease mice

2021 ◽  
Vol 1762 ◽  
pp. 147437
Author(s):  
Tanita Pairojana ◽  
Sarayut Phasuk ◽  
Pavithra Suresh ◽  
Shun-Ping Huang ◽  
Narawut Pakaprot ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Gender Differences ◽  
Age And Gender ◽  
Behavioral Phenotypes ◽  
Age And Gender Differences ◽  
And Gender

scholarly journals Salivaomics as a Potential Tool for Predicting Alzheimer’s Disease During the Early Stages of Neurodegeneration

2021 ◽  
pp. 1-13
Author(s):  
Maxime François ◽  
Avinash Karpe ◽  
Jian-Wei Liu ◽  
David Beale ◽  
Maryam Hor ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Healthy Controls ◽  
Age And Gender ◽  
Cognitively Normal ◽  
Cellular Processes ◽  
Cellular Pathways ◽  
And Gender ◽  
New Biomarkers ◽  
Potential Tool

Background: The metabolomic and proteomic basis of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) is poorly understood and the relationships between systemic abnormalities in metabolism and AD/AMCI pathogenesis are unclear. Objective: The aim of the study was to compare the metabolomic and proteomic signature of saliva from cognitively normal and patients diagnosed with MCI or AD, to identify specific cellular pathways altered with the progression of the disease. Methods: We analyzed 80 saliva samples from individuals with MCI or AD as well as age- and gender-matched healthy controls. Saliva proteomic and metabolomic analyses were conducted utilizing mass spectrometry methods and data combined using pathway analysis. Results: We found significant alterations in multiple cellular pathways, demonstrating that at the omics level, disease progression impacts numerous cellular processes. Multivariate statistics using SIMCA showed that partial least squares-data analysis could be used to provide separation of the three groups. Conclusion: This study found significant changes in metabolites and proteins from multiple cellular pathways in saliva. These changes were associated with AD, demonstrating that this approach might prove useful to identify new biomarkers based upon integration of multi-omics parameters.

scholarly journals Individual Differences and Features of Self-Reported Memory Lapses as Risk Factors for Alzheimer’s Disease: Protocol for a Coordinated Analysis Across Two Longitudinal Datasets (Preprint)

2020 ◽  
Author(s):  
Jacqueline Mogle ◽  
Nikki Hill ◽  
Jennifer Turner
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Cognitive Aging ◽  
Screening Tools ◽  
Accurate Identification ◽  
Age And Gender ◽  
Memory Problems ◽  
And Gender ◽  
The Impact

UNSTRUCTURED Increasing evidence promotes the clinical utility of self-reported memory problems for detecting early impairment associated with Alzheimer’s disease (AD). However, past work investigating memory problems often conflated the types of problems (i.e., retrospective and prospective) with their features (i.e., frequency and consequences). This bias limits the specificity of traditional measures of memory problems and minimizes their ability to detect differential trajectories associated with cognitive decline. In the present study, we use a novel measure of self-reported memory problems that uses daily reports of memory lapses to disentangle types from features to analyze the impact of each dimension in two longitudinal datasets. Further, this study explores the individual difference factors of age and gender as potential moderators of the relationships between self-reported memory lapses and objective cognitive decline. This study uses multilevel, coordinated analyses across two measurement burst datasets to examine the links between features and consequences of memory lapses (retrospective and prospective) and their association with objective cognitive decline. The current sample (n = 535; ages 50-85 years; 61% women) is drawn from two ongoing, nationally funded research studies: the Effects of Stress on Cognitive Aging, Physiology, and Emotion Study and the Einstein Aging Study. Both studies assess the daily experience of memory lapses, including the type as well as the emotional and functional outcomes, and objective measures of cognition such as processing speed and episodic memory. We will use multilevel modeling to test our conceptual model that differences in frequency and types of memory lapses show differential trends in their relationships with cognitive decline and that these relationships vary by age and gender of participant. The early and accurate identification of individuals most at risk for cognitive decline is of paramount importance. Previous research exploring self-reported memory problems and AD is promising, however limitations in measurement may explain prior reports of inconsistences. The current study addresses these concerns by examining daily reports of memory lapses, how these vary by age and gender, and their relationship with objective cognitive performance. Overall this study aims to identify key features of daily memory lapses and the differential trajectories that best predict cognitive decline to help inform future AD risk screening tools.

Age and gender as risk modifiers of ApoE-ϵ4 in Alzheimer's disease

2000 ◽  
Vol 21 ◽  
pp. 247
Author(s):  
Brent J. Small ◽  
Laila Abdullah ◽  
Melissa J. Freeman ◽  
Fiona Crawford ◽  
Ranjan Duara ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Age And Gender ◽  
And Gender ◽  
Risk Modifiers

scholarly journals Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimer’s disease

Bioimpacts ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. 219-225 ◽  
Author(s):  
Elham Mehdizadeh ◽  
Mohammad Khalaj-Kondori ◽  
Zeinab Shaghaghi-Tarakdari ◽  
Saeed Sadigh-Eteghad ◽  
Mahnaz Talebi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Gene Polymorphisms ◽  
Neurodegenerative Disorder ◽  
Late Onset ◽  
Salting Out ◽  
Age And Gender ◽  
Blood Samples ◽  
Significant Difference ◽  
And Gender

Introduction: Alzheimer’s disease (AD), which is a progressive neurodegenerative disorder, causes structural and functional brain disruption. MS4A6A, TREM2, and CD33 gene polymorphisms loci have been found to be associated with the pathobiology of late-onset AD (LOAD). In the present study, we tested the hypothesis of association of LOAD with rs983392, rs75932628, and rs3865444 polymorphisms in MS4A6A, TREM2, CD33 genes, respectively.Methods: In the present study, 113 LOAD patients and 100 healthy unrelated age- and gender-matched controls were selected. DNA was extracted from blood samples by the salting-out method and the genotyping was performed by RFLP-PCR. Electrophoresis was carried out on agarose gel. Sequencing was thereafter utilized for the confirmation of the results. Results: Only CD33 rs3865444 polymorphism revealed a significant difference in the genotypic frequencies of GG (P = 0.001) and GT (P = 0.001), and allelic frequencies of G (P = 0.033) and T (P = 0.03) between LOAD patients and controls. Conclusion: The evidence from the present study suggests that T allele of CD33 rs3865444 polymorphism is associated with LOAD in the studied Iranian population.

Age and gender-specific effects of a myeloperoxidase promoter polymorphism in Alzheimer's disease

2000 ◽  
Vol 21 ◽  
pp. 249
Author(s):  
Mark Morris ◽  
Fiona Crawford ◽  
Melissa J. Freeman ◽  
John Schinka ◽  
Mike Gold ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Promoter Polymorphism ◽  
Age And Gender ◽  
Specific Effects ◽  
And Gender ◽  
Gender Specific
Sign in / Sign up

Export Citation Format

Share Document